Pluristem Therapeutics (NASDAQ: PSTI) and GenVec (NASDAQ:GNVC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Pluristem Therapeutics and GenVec’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics N/A -100.14% -80.04%
GenVec -3,748.25% -648.22% -271.77%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pluristem Therapeutics and GenVec, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluristem Therapeutics 0 0 3 0 3.00
GenVec 0 2 0 0 2.00

Pluristem Therapeutics currently has a consensus price target of $3.83, suggesting a potential upside of 138.10%. GenVec has a consensus price target of $7.00, suggesting a potential upside of Infinity. Given GenVec’s higher probable upside, analysts clearly believe GenVec is more favorable than Pluristem Therapeutics.

Valuation and Earnings

This table compares Pluristem Therapeutics and GenVec’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics $2.85 million 61.07 -$27.81 million ($0.32) -5.03
GenVec N/A N/A N/A ($3.67) N/A

GenVec has lower revenue, but higher earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than GenVec, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

4.3% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 6.2% of GenVec shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 8.1% of GenVec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pluristem Therapeutics beats GenVec on 7 of the 11 factors compared between the two stocks.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

GenVec Company Profile

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.